28380486|t|Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women
28380486|a|Neurokinin B (NKB) and kisspeptin are obligate for normal gonadotropin secretion, and links between GnRH pulsatility and vasomotor symptoms have been proposed. Using a selective NKB receptor (NK3R) antagonist, the role of NKB in the hypergonadotropic state in menopausal women was explored. Eleven postmenopausal women were administered the NK3R antagonist MLE4901, 40 mg twice daily orally for 7 days. 10- min blood sampling for 8 h was performed before and on the last day of NK3R antagonist treatment for LH pulsatility analysis with kisspeptin-10 (0.3 µg/kg iv bolus) administered at 6 h on both days. Hot flash frequency and severity were self-reported for 7 days before and during NK3R antagonist administration. LH fell from 29.3 ± 4.1 to 24.4 ± 3.8 IU/l (p < 0.05) after 7 days of NK3R antagonist, with no change in FSH. Basal (nonpulsatile) LH secretion was reduced (549.0 ± 70.8 vs. 366.1 ± 92.1 IU/L/6 h, p = 0.006) and while LH pulse frequency did not change in the group as a whole (0.8 ± 0.1 to 0.7 ± 0.1 pulses /h, ns), it did fall in the 8/11 women with hot flashes, (1.0 ± 0.1 to 0.7 ± 0.1 pulses /h, p < 0.05). These women also reported a reduction in hot flash frequency (3.4 ± 1.2 to 1.0 ± 0.6 hot flashes / day, p = 0.008) whist taking NK3R antagonist. Kisspeptin-10 did not affect LH secretion with or without NK3R antagonist. The administration of a NK3R antagonist indicates a role for NKB in the regulation of LH / GnRH in postmenopausal women whereas the lack of response to kisspeptin may reflect the hypoestrogenic state. These data support a link between LH / GnRH pulsatility and vasomotor symptoms and NK3R antagonism as a potential therapeutic approach.
28380486	0	21	Neurokinin 3 Receptor	T116,T192	C0068603
28380486	22	32	Antagonism	T054	C0680242
28380486	51	63	Neurokinin B	T116,T123	C0027847
28380486	71	81	Regulation	T038	C1327622
28380486	85	107	Gonadotropin Secretion	T042	C1819179
28380486	112	123	Hot Flashes	T184	C0600142
28380486	127	141	Postmenopausal	T033	C0232970
28380486	142	147	Women	T098	C0043210
28380486	148	160	Neurokinin B	T116,T123	C0027847
28380486	162	165	NKB	T116,T123	C0027847
28380486	171	181	kisspeptin	T116,T123	C3146273
28380486	206	228	gonadotropin secretion	T042	C1819179
28380486	234	239	links	T080	C0439849
28380486	248	252	GnRH	T116,T121,T125	C0023610
28380486	253	264	pulsatility	T080	C0577317
28380486	269	287	vasomotor symptoms	T184	C0750152
28380486	326	338	NKB receptor	T116,T192	C0068603
28380486	340	344	NK3R	T116,T192	C0068603
28380486	346	356	antagonist	T120	C0243076
28380486	370	373	NKB	T116,T123	C0027847
28380486	381	404	hypergonadotropic state	T169	C1442792
28380486	408	418	menopausal	T039	C0025320
28380486	419	424	women	T098	C0043210
28380486	446	460	postmenopausal	T033	C0232970
28380486	461	466	women	T098	C0043210
28380486	472	484	administered	T169	C1521801
28380486	489	493	NK3R	T116,T192	C0068603
28380486	494	504	antagonist	T120	C0243076
28380486	505	512	MLE4901	T109,T121	C2975298
28380486	526	531	daily	T079	C0332173
28380486	532	538	orally	T082	C0442027
28380486	545	549	days	T079	C0439228
28380486	555	558	min	T079	C0439232
28380486	559	573	blood sampling	T060	C0190979
28380486	619	622	day	T079	C0439228
28380486	626	630	NK3R	T116,T192	C0068603
28380486	631	641	antagonist	T120	C0243076
28380486	642	651	treatment	T169	C0039798
28380486	656	658	LH	T116,T121,T125	C0023607
28380486	659	670	pulsatility	T080	C0577317
28380486	671	679	analysis	T062	C0936012
28380486	685	698	kisspeptin-10	T116,T123	C1721258
28380486	710	718	iv bolus	T169	C1522229
28380486	720	732	administered	T169	C1521801
28380486	748	752	days	T079	C0439228
28380486	754	763	Hot flash	T184	C0600142
28380486	764	773	frequency	T080	C1561548
28380486	778	786	severity	T080	C0439793
28380486	812	816	days	T079	C0439228
28380486	835	839	NK3R	T116,T192	C0068603
28380486	840	850	antagonist	T120	C0243076
28380486	851	865	administration	T061	C1533734
28380486	867	869	LH	T116,T121,T125	C0023607
28380486	929	933	days	T079	C0439228
28380486	937	941	NK3R	T116,T192	C0068603
28380486	942	952	antagonist	T120	C0243076
28380486	972	975	FSH	T116,T121,T125	C0733758
28380486	977	982	Basal	T081	C1442488
28380486	984	996	nonpulsatile	T033	C0243095
28380486	998	1000	LH	T116,T121,T125	C0023607
28380486	1001	1010	secretion	T038	C0036536
28380486	1015	1022	reduced	T080	C0392756
28380486	1085	1087	LH	T116,T121,T125	C0023607
28380486	1088	1103	pulse frequency	T080	C1561548
28380486	1126	1131	group	T078	C0441833
28380486	1167	1173	pulses	T039	C0391850
28380486	1207	1212	women	T098	C0043210
28380486	1218	1229	hot flashes	T184	C0600142
28380486	1255	1261	pulses	T039	C0391850
28380486	1283	1288	women	T098	C0043210
28380486	1305	1314	reduction	T080	C0392756
28380486	1318	1327	hot flash	T184	C0600142
28380486	1328	1337	frequency	T080	C1561548
28380486	1362	1373	hot flashes	T184	C0600142
28380486	1376	1379	day	T079	C0439228
28380486	1405	1409	NK3R	T116,T192	C0068603
28380486	1410	1420	antagonist	T120	C0243076
28380486	1422	1435	Kisspeptin-10	T116,T123	C1721258
28380486	1451	1453	LH	T116,T121,T125	C0023607
28380486	1454	1463	secretion	T038	C0036536
28380486	1480	1484	NK3R	T116,T192	C0068603
28380486	1485	1495	antagonist	T120	C0243076
28380486	1501	1515	administration	T061	C1533734
28380486	1521	1525	NK3R	T116,T192	C0068603
28380486	1526	1536	antagonist	T120	C0243076
28380486	1558	1561	NKB	T116,T123	C0027847
28380486	1569	1579	regulation	T038	C1327622
28380486	1583	1585	LH	T116,T121,T125	C0023607
28380486	1588	1592	GnRH	T116,T121,T125	C0023610
28380486	1596	1610	postmenopausal	T033	C0232970
28380486	1611	1616	women	T098	C0043210
28380486	1629	1645	lack of response	T033	C1320680
28380486	1649	1659	kisspeptin	T116,T123	C3146273
28380486	1676	1696	hypoestrogenic state	T033	C0243095
28380486	1704	1708	data	T078	C1511726
28380486	1719	1723	link	T080	C0439849
28380486	1732	1734	LH	T116,T121,T125	C0023607
28380486	1737	1741	GnRH	T116,T121,T125	C0023610
28380486	1742	1753	pulsatility	T080	C0577317
28380486	1758	1776	vasomotor symptoms	T184	C0750152
28380486	1781	1785	NK3R	T116,T192	C0068603
28380486	1786	1796	antagonism	T054	C0680242
28380486	1812	1832	therapeutic approach	T061	C0087111